Vedolizumab therapy for pediatric steroid-refractory gastrointestinal acute graft-versus-host disease

被引：0
作者：
Kyohei Isshiki
Takahiro Kamiya
Akifumi Endo
Kentaro Okamoto
Tomoo Osumi
Toshinao Kawai
Katsuhiro Arai
Daisuke Tomizawa
Kazuo Ohtsuka
Masakazu Nagahori
Kohsuke Imai
Motohiro Kato
Hirokazu Kanegane
机构：
[1] National Center for Child Health and Development,Children’s Cancer Center
[2] Tokyo Medical and Dental University Hospital,Department of Pediatrics
[3] Tokyo Medical and Dental University Hospital,Department of Pediatric Surgery
[4] National Center for Child Health and Development,Division of Immunology
[5] National Center for Child Health and Development,Division of Gastroenterology
[6] Tokyo Medical and Dental University Hospital,Department of Gastroenterology and Hepatology
来源：
International Journal of Hematology | 2022年 / 115卷
关键词：
Vedolizumab; GVHD; Children; Gastrointestinal tract; Refractory;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Vedolizumab, an immunosuppressive drug that acts locally on the gastrointestinal tract, is mainly used for the treatment of inflammatory bowel disease, and has been reported to be effective against gastrointestinal acute graft-versus-host disease (GI-aGVHD) in adults. However, there is insufficient evidence for pediatric GI-aGVHD. We used vedolizumab to treat three cases of GI-aGVHD in patients aged 1.5–4.4 years. It was significantly effective in two patients and did not cause serious side effects in any patient. Vedolizumab might be effective and safe for pediatric GI-aGVHD refractory to other treatments, but this must be confirmed in future studies.
引用
收藏
页码：590 / 594
页数：4
相关论文
共 50 条
  • [1] Vedolizumab therapy for pediatric steroid-refractory gastrointestinal acute graft-versus-host disease
    Isshiki, Kyohei
    Kamiya, Takahiro
    Endo, Akifumi
    Okamoto, Kentaro
    Osumi, Tomoo
    Kawai, Toshinao
    Arai, Katsuhiro
    Tomizawa, Daisuke
    Ohtsuka, Kazuo
    Nagahori, Masakazu
    Imai, Kohsuke
    Kato, Motohiro
    Kanegane, Hirokazu
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2022, 115 (04) : 590 - 594
  • [2] Vedolizumab plus basiliximab as second-line therapy for steroid-refractory lower gastrointestinal acute graft-versus-host disease
    Gao, Zicheng
    Fan, Zhiping
    Liu, Zhi
    Ye, Xu
    Zeng, Yunxin
    Xuan, Li
    Huang, Fen
    Lin, Ren
    Sun, Jing
    Liu, Qifa
    Xu, Na
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [3] Vedolizumab for Steroid Refractory Lower Gastrointestinal Tract Graft-Versus-Host Disease
    Mehta, Rohtesh S.
    Saliba, Rima M.
    Jan, Anna
    Shigle, Terri Lynn
    Wang, Emily
    Nieto, Yago
    Ciurea, Stefan O.
    Oran, Betul
    Im, Jin
    Olson, Amanda
    Marin, David
    Qazilbash, Muzaffar
    Khouri, Issa
    Rondon, Gabriela
    Anderlini, Paolo
    Rezvani, Katayoun
    Popat, Uday
    Kebriaei, Partow
    Shpall, Elizabeth
    Champlin, Richard
    Alousi, Amin
    TRANSPLANTATION AND CELLULAR THERAPY, 2021, 27 (03): : 272.e1 - 272.e5
  • [4] Vedolizumab for second-line treatment of steroid-refractory gastrointestinal late acute graft-versus-host disease
    Zu, Yingling
    Gui, Ruirui
    Li, Zhen
    Wang, Juan
    Li, Pei
    Liu, Ying
    Dong, Xiaofeng
    Zhou, Jian
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2024, 15
  • [5] Etanercept as Treatment of Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric Patients
    Faraci, Maura
    Calevo, Maria Grazia
    Giardino, Stefano
    Leoni, Massimiliano
    Ricci, Erica
    Castagnola, Elio
    Lanino, Edoardo
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (04) : 743 - 748
  • [6] Combination Therapy with Inolimomab and Etanercept for Severe Steroid-Refractory Acute Graft-versus-Host Disease
    van Groningen, Lenneke F. J.
    Liefferink, Aleida M.
    de Haan, Anton F. J.
    Schaap, Nicolaas P. M.
    Donnelly, J. Peter
    Blijlevens, Nicole M. A.
    van der Velden, Walter J. F. M.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (01) : 179 - 182
  • [7] Effectiveness of intra-arterial steroid administration for the treatment of steroid-refractory acute gastrointestinal graft-versus-host disease
    Berczi, V
    Toth, A.
    Tatai, G.
    Fabian, J.
    Remenyi, P.
    Masszi, T.
    CLINICAL RADIOLOGY, 2019, 74 (04) : 301 - 305
  • [8] Ruxolitinib as Salvage Therapy in Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric Hematopoietic Stem Cell Transplant Patients
    Khandelwal, Pooja
    Teusink-Cross, Ashley
    Davies, Stella M.
    Nelson, Adam S.
    Dandoy, Christopher E.
    El-Bietar, Javier
    Marsh, Rebecca A.
    Kumar, Ashish R.
    Grimley, Michael S.
    Jodele, Sonata
    Myers, Kasiani C.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2017, 23 (07) : 1122 - 1127
  • [9] Ruxolitinib for steroid-refractory graft-versus-host disease: A case series
    Lancman, Guido
    Coltoff, Alexander
    Steinberg, Amir
    HEMATOLOGICAL ONCOLOGY, 2018, 36 (03) : 611 - 613
  • [10] Acute Steroid-Refractory Gastrointestinal Graft-Versus-Host Disease Is Not Associated With Significant Differences in Gut Taxonomic Composition Compared to Steroid-Sensitive Gastrointestinal Graft-Versus-Host Disease Immediately Before Onset of Disease
    Zeng, Ke
    Brewster, Ryan
    Kang, Joyce B.
    Tkachenko, Ekaterina
    Brooks, Erin
    Bhatt, Ami S.
    Fodor, Anthony A.
    Andermann, Tessa M.
    TRANSPLANTATION AND CELLULAR THERAPY, 2024, 30 (02): : 237.e1 - 237.e9
12345